DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2005-08-26

Last Posted Date: 2011-04-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 300

Registration Number: NCT00135369

Locations: 🇵🇷
Local Institution, San Juan, Puerto Rico

A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Atazanvir/ritonavir + efavirenz

First Posted Date: 2005-08-26

Last Posted Date: 2011-04-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 60

Registration Number: NCT00135343

Locations: 🇺🇸
Local Institution, Hampton, Virginia, United States

A Study of Prevalence of the I50L Mutation When ATV Treated Patients Fail the Regimen

Completed

Conditions: HIV Infections

First Posted Date: 2005-08-26

Last Posted Date: 2011-04-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 5000

Registration Number: NCT00135447

Locations: 🇺🇸
Biogenomx Research Institute, LLC/CHC1-AP, Hollywood, Florida, United States
🇺🇸
Infectious Disease Group of Atlanta, Atlanta, Georgia, United States
🇺🇸
Family Healthcare of Atlanta, PC, Atlanta, Georgia, United States

and more 78 locations

Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2005-08-26

Last Posted Date: 2011-04-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 25

Registration Number: NCT00135434

Locations: 🇺🇸
Clinical Pharmacology Unit, Bristol-Myers Squibb Company, Hamilton, New Jersey, United States

Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept
Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
Drug: Anti-Tumor Necrosing Factor (TNF) Therapy

First Posted Date: 2005-07-29

Last Posted Date: 2012-02-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1286

Registration Number: NCT00124982

Locations: 🇬🇧
Local Institution, Leeds, North Yorkshire, United Kingdom

Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: placebo
Drug: Abatacept

First Posted Date: 2005-07-28

Last Posted Date: 2015-04-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 56

Registration Number: NCT00124449

Locations: 🇬🇧
Local Institution, Leeds, North Yorkshire, United Kingdom

Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML

Phase 3

Completed

Conditions: Myeloid Leukemia, Chronic, Chronic-Phase

Interventions: Drug: dasatinib

First Posted Date: 2005-07-25

Last Posted Date: 2016-08-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 724

Registration Number: NCT00123474

Locations: 🇺🇸
Kaiser Permanente Medical Center, Vallejo, California, United States
🇺🇸
University Of Maryland, Baltimore, Maryland, United States
🇺🇸
Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States

and more 38 locations

Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

Phase 3

Completed

Conditions: Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Myeloid Leukemia, Chronic, Accelerated Phase

Interventions: Drug: dasatinib

First Posted Date: 2005-07-25

Last Posted Date: 2014-11-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 638

Registration Number: NCT00123487

Locations: 🇺🇸
The University Of North Carolina At Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸
Washington University School Of Medicine, Saint Louis, Missouri, United States
🇺🇸
Emory University School Of Medicine, Atlanta, Georgia, United States

and more 24 locations

Remission and Joint Damage Progression in Early Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept
Drug: placebo
Drug: methotrexate

First Posted Date: 2005-07-22

Last Posted Date: 2010-11-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1052

Registration Number: NCT00122382

Locations: 🇬🇧
Local Institution, Newcastle, Northumberland, United Kingdom
🇺🇸
Lion Research, Norman, Oklahoma, United States
🇺🇸
Diagnostic Rheumatology And Research, Indianapolis, Indiana, United States

and more 17 locations

Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: atazanavir/ritonavir +2 NRTIs (immediate Switch Group)
Drug: LPV/r +2 NRTIs (Delayed/optional Switch Group)

First Posted Date: 2005-07-18

Last Posted Date: 2010-02-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 192

Registration Number: NCT00120393

Locations: 🇨🇦
Local Institution, Montreal, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy